Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.09 USD

113.09
11,127,844

-1.64 (-1.43%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Bristol-Myers Gets FTC Clearance for Celgene Acquisition

Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.

Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

Tirthankar Chakraborty headshot

5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000

We highlight blue-chip companies slated to gain in the near term as they have large market capitalization, strong balance sheet and solid cash flow.

AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

Kinjel Shah headshot

4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

Merck's Ebola Vaccine Gets Conditional Approval in Europe

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health

Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

Mark Vickery headshot

Top Analyst Reports for Mastercard, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), UnitedHealth Group (UNH) and Merck (MRK).

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.